Fluoxetine as a potential pharmacotherapy for methamphetamine dependence: Studies in mice

Annals of the New York Academy of Sciences

Volumn 1074, Issue , 2006, Pages 295-302

  Takamatsu, Yukio ^a   Yamamoto, Hideko ^a   Ogai, Yasukazu ^a   Hagino, Yoko ^a   Markou, Athina ^b   Ikeda, Kazutaka ^a  

^a TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Conditioned place preference; Fluoxetine; Locomotor activity; Methamphetamine; Mice; Sensitization

Indexed keywords

BRAIN MONOAMINE; COCAINE; DOPAMINE TRANSPORTER; FLUOXETINE; METHAMPHETAMINE; PSYCHOSTIMULANT AGENT; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; SODIUM CHLORIDE;

ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; CONFERENCE PAPER; CONTROLLED STUDY; DEPRESSION; DRUG DEPENDENCE; DRUG INDICATION; KNOCKOUT MOUSE; LOCOMOTION; MALE; METHAMPHETAMINE DEPENDENCE; MOUSE; NONHUMAN; PLACE PREFERENCE; REWARD; TREATMENT OUTCOME;

EID: 33749571743     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1369.026     Document Type: Conference Paper

References (27)

1. UNITED NATIONS OFFICE FOR DRUG CONTROL AND CRIME PREVENTION Ed. 2005. World Drug Report 2005. Oxford University Press. New York, NY.
2. UJIKE, H. 2002. Stimulant-induced psychosis and schizophrenia: the role of sensitization. Curr. Psychiatry Rep. 4: 177-184.
3. NATIONAL INSTITUTE ON DRUG ABUSE (NIDA) Ed. 2002. Research Report Series: Methamphetamine Abuse and Addiction. National Institutes of Health. Maryland, MA.
4. SORA, I. et al. 1998. Cocaine reward models: conditioned place preference can be established in dopamine- and in serotonin-transporter knockout mice. Proc. Natl. Acad. Sci. USA 95: 7699-7704.
5. ROCHA, B.A. et al. 1998. Cocaine self-administration in dopamine-transporter knockout mice. Nat. Neurosci. 1: 132-137.
6. SORA, I. et al. 2001. Molecular mechanisms of cocaine reward: combined dopamine and serotonin transporter knockouts eliminate cocaine place preference. Proc. Natl. Acad. Sci. USA 98: 5300-5305.
7. SHEN, H.-W. et al. 2004. Regional differences in extracellular dopamine and serotonin assessed by in vivo microdialysis in mice lacking dopamine and/or serotonin transporters. Neuropsychopharmacology 29: 1790-1799.
8. HOFFMAN, D.C. & R.J. BENINGER. 1989. Preferential stimulation of D1 or D2 receptors disrupts food-rewarded operant responding in rats. Pharmacol. Biochem. Behav. 34: 923-925.
9. IDE, S. et al. 2004. Buprenorphine antinociception is abolished, but naloxone-sensitive reward is retained, in mu-opioid receptor knockout mice. Neuropsychopharmacology 29: 1656-1663.
10. KITANAKA, N. et al. 2005. Inhibition of methamphetamine-induced hyperlocomotion in mice by clorgyline, a monoamine oxidase-A inhibitor, through alteration of the 5-hydroxytriptamine turnover in the striatum. Neuroscience 130: 295-308.
11. SULZER, D. et al. 1995. Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. J. Neurosci. 15: 4102-4108.
12. HOTCHKISS, A.J. & J.W. GIBB. 1980. Long-term effects of multiple doses of methamphetamine on tryptophan hydroxylase and tyrosine hydroxylase activity in rat brain. J. Pharmacol. Exp. Ther. 214: 257-262.
13. FLECKENSTEIN, A.E. et al. 1997. Methamphetamine-induced decrease in tryptophan hydroxylase activity: role of 5-hydroxytryptaminergic transporters. Eur. J. Pharmacol. 324: 179-186.
14. + channels by fluoxetine (Prozac). Br. J. Pharmacol. 138: 1119-1128.
15. + channels by antidepressant drugs. J. Pharmacol. Exp. Ther. 284: 208-214.
16. CHOI, J.-S. et al. 1999. Mechanism of fluoxetine block of cloned voltage-activated potassium channel Kv1.3. J. Pharmacol. Exp. Ther. 291: 1-6.
17. YEUNG, S.Y. et al. 1999. Inhibition of neuronal KV potassium currents by the antidepressant drug, fluoxetine. Br. J. Pharmacol. 128: 1609-1615.
18. DEÁK, F.B. et al. 2000. Inhibition of voltage-gated calcium channels by fluoxetine in rat hippocampal pyramidal cells. Neuropharmacology 39: 1029-1036.
19. CHOI, B.H. et al. 2001. Effects of norfluoxetine, the major metabolite of fluoxetine, on the cloned neuronal potassium channel Kv3.1. Neuropharmacology 41: 443-453.
20. + channel hKv1.5. J. Pharmacol. Exp. Ther. 298: 1108-1119.
21. THOMAS, D. et al. 2002. The antidepressant drug fluoxetine is an inhibitor of human ether-a-go-go-related gene (HERG) potassium channels. J. Pharmacol. Exp. Ther. 300: 543-548.
22. MAERTENS, C. et al. 1999. Block by fluoxetine of volume-regulated anion channels. Br. J. Pharmacol. 126: 508-514.
23. Ni, Y.G. & R. MILEDI. 1997. Blockage of 5HT2C serotonin receptors by fluoxetine (Prozac). Proc. Natl. Acad. Sci. USA 94: 2036-2040.
24. FAN, P. 1994. Effects of antidepressants on the inward current mediated by 5-HT3 receptors in rat nodose ganglion neurones. Br. J. Pharmacol. 112: 741-744.
25. GARCÍA-COLUNGA et al. 1997. Blockage of muscle and neuronal nicotinic acetylcholine receptors by fluoxetine (Prozac). Proc. Natl. Acad. Sci. USA 94: 2041-2044.
26. MAGGI, L. et al. 1998. Effects of fluoxetine on wild and mutant neuronal alpha 7 nicotinic receptors. Mol. Psychiatry 3: 350-355.
27. MORGAN, A.D. et al. 2003. Decreased cocaine self-administration in Kir3 potassium channel subunit knockout mice. Neuropsychopharmacology 28: 932-938.